2.11 USD
-0.09 (-4.09%)
We assign a fundamental rating of 2 out of 10 to VTAK. VTAK was compared to 187 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of VTAK have multiple concerns. VTAK is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year VTAK has reported negative net income.
VTAK had a negative operating cash flow in the past year.
VTAK had negative earnings in each of the past 5 years.
In the past 5 years VTAK always reported negative operating cash flow.
1.2 Ratios
VTAK has a worse Return On Assets (-94.12%) than 78.61% of its industry peers.
With a Return On Equity value of -354.30%, VTAK is not doing good in the industry: 78.61% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -94.12% | ||
| ROE | -354.3% | ||
| ROIC | N/A |
ROA(3y)-156.76%
ROA(5y)-139.44%
ROE(3y)-270.77%
ROE(5y)-233.22%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 92.33%, VTAK belongs to the best of the industry, outperforming 98.40% of the companies in the same industry.
VTAK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.33% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VTAK does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VTAK has more shares outstanding
VTAK has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -18.07, we must say that VTAK is in the distress zone and has some risk of bankruptcy.
VTAK has a worse Altman-Z score (-18.07) than 88.77% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that VTAK is not too dependend on debt financing.
VTAK has a better Debt to Equity ratio (0.00) than 73.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -18.07 |
ROIC/WACCN/A
WACC7.55%
2.3 Liquidity
VTAK has a Current Ratio of 0.44. This is a bad value and indicates that VTAK is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of VTAK (0.44) is worse than 93.58% of its industry peers.
VTAK has a Quick Ratio of 0.44. This is a bad value and indicates that VTAK is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of VTAK (0.43) is worse than 92.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.44 | ||
| Quick Ratio | 0.43 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 70.00% over the past year.
Looking at the last year, VTAK shows a very strong growth in Revenue. The Revenue has grown by 37.61%.
Measured over the past years, VTAK shows a very strong growth in Revenue. The Revenue has been growing by 167.26% on average per year.
EPS 1Y (TTM)70%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.12%
Revenue 1Y (TTM)37.61%
Revenue growth 3Y167.27%
Revenue growth 5YN/A
Sales Q2Q%127.96%
3.2 Future
VTAK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.75% yearly.
VTAK is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 312.31% yearly.
EPS Next Y96.27%
EPS Next 2Y40.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year533.33%
Revenue Next 2Y312.31%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VTAK. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VTAK. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as VTAK's earnings are expected to grow with 40.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.75%
EPS Next 3YN/A
5. Dividend
5.1 Amount
VTAK does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NYSEARCA:VTAK (12/18/2025, 11:25:53 AM)
2.11
-0.09 (-4.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners0.58%
Inst Owner Change-99.99%
Ins Owners0.74%
Ins Owner Change4.3%
Market Cap3.52M
Revenue(TTM)600.00K
Net Income(TTM)-24.06M
Analysts85.71
Price Target38.76 (1736.97%)
Short Float %2.21%
Short Ratio0.19
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-59.17%
Min Revenue beat(2)-65.07%
Max Revenue beat(2)-53.27%
Revenue beat(4)0
Avg Revenue beat(4)-65.2%
Min Revenue beat(4)-91.15%
Max Revenue beat(4)-51.31%
Revenue beat(8)0
Avg Revenue beat(8)-68.97%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5.87 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.52 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-73.84
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-6.14
FCFYN/A
OCF(TTM)-6.13
OCFYN/A
SpS0.36
BVpS4.07
TBVpS-9.86
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -94.12% | ||
| ROE | -354.3% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.33% | ||
| FCFM | N/A |
ROA(3y)-156.76%
ROA(5y)-139.44%
ROE(3y)-270.77%
ROE(5y)-233.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1.08% | ||
| Cap/Sales | 3.83% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.44 | ||
| Quick Ratio | 0.43 | ||
| Altman-Z | -18.07 |
F-Score5
WACC7.55%
ROIC/WACCN/A
Cap/Depr(3y)3.63%
Cap/Depr(5y)N/A
Cap/Sales(3y)51.53%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.12%
EPS Next Y96.27%
EPS Next 2Y40.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)37.61%
Revenue growth 3Y167.27%
Revenue growth 5YN/A
Sales Q2Q%127.96%
Revenue Next Year533.33%
Revenue Next 2Y312.31%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.89%
OCF growth 3YN/A
OCF growth 5YN/A
CATHETER PRECISION INC / VTAK FAQ
What is the ChartMill fundamental rating of CATHETER PRECISION INC (VTAK) stock?
ChartMill assigns a fundamental rating of 2 / 10 to VTAK.
What is the valuation status of CATHETER PRECISION INC (VTAK) stock?
ChartMill assigns a valuation rating of 1 / 10 to CATHETER PRECISION INC (VTAK). This can be considered as Overvalued.
Can you provide the profitability details for CATHETER PRECISION INC?
CATHETER PRECISION INC (VTAK) has a profitability rating of 1 / 10.
How financially healthy is CATHETER PRECISION INC?
The financial health rating of CATHETER PRECISION INC (VTAK) is 1 / 10.
What is the earnings growth outlook for CATHETER PRECISION INC?
The Earnings per Share (EPS) of CATHETER PRECISION INC (VTAK) is expected to grow by 96.27% in the next year.